Amneal Pharmaceuticals Inc (AMRX)
6.06
+0.66
(+12.22%)
USD |
NASDAQ |
Apr 24, 16:00
6.06
0.00 (0.00%)
After-Hours: 17:35
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.860B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 231.3% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.4501 |
| Price to Book Value | 94.05 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 133.49 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 94.77% |
Profile
| Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities. |
| URL | https://www.amneal.com |
| Investor Relations URL | https://investors.amneal.com/investor-relations/ |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 03, 2024 |
| Last Earnings Release | Mar. 01, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities. |
| URL | https://www.amneal.com |
| Investor Relations URL | https://investors.amneal.com/investor-relations/ |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 03, 2024 |
| Last Earnings Release | Mar. 01, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |